The global hepatic encephalopathy drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The market growth is majorly attributed owing to the increasing R&D activities as well as clinical trials for hepatic encephalopathy drugs. For instance, in 2018, Norgine B.V. announced positive results for the clinical trial, which was conducted for testing the safety and efficacy of rifaximin in liver cirrhosis and chronic hepatic encephalopathy. As per this trial, rifaximin-? reduced systemic inflammation, immune dysfunction, and infection susceptibility in patients suffering from liver cirrhosis.
To Request a Sample of our Report on Global Hepatic Encephalopathy Drugs Market: https://www.omrglobal.com/request-sample/hepatic-encephalopathy-drugs-market
Based on the geography, North America is anticipated to hold a substantial share in the global hepatic encephalopathy drugs market during the forecast period, owing to the increasing prevalence of hepatic encephalopathy in this region. For instance, according to National Center for Biotechnology Information (NCBI), in September 2020, around 7-11 million cases of hepatic encephalopathy were prevalent in the US, with around 150,000 patients being newly diagnosed each year. Out of the newly diagnosed patients, around 20% have liver cirrhosis, and almost 60% of patients suffer from chronic hepatitis C either alone or along with the alcohol-related liver disease. Moreover, symptoms of hepatic encephalopathy are observed in around 70% of patients with liver cirrhosis.
Some key players operating in the market include Lupin Ltd., Bausch Health Companies Inc., and Mallinckrodt LLC, among others. The market players are focusing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launches and development in the existing product portfolio, and so on. For instance, in April 2020, Umecrine Cognition AB, a Karolinska Development portfolio company, reported positive results for a phase II clinical trial for the drug candidate golexanolone, which was tested on patients with the risk of developing hepatic encephalopathy.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Lupin Ltd., Bausch Health Companies Inc., and Mallinckrodt LLC, among others.
(Get 15% Discount on Buying this Report)
A full Report of Global Hepatic Encephalopathy Drugs Market is Available at: https://www.omrglobal.com/industry-reports/hepatic-encephalopathy-drugs-market
Global Hepatic Encephalopathy Drugs Market Report by Segment
By Drug Class
• Antibiotics
• L-Ornithine L-Aspartate
• Laxatives
• Others
By Route of Administration
• Oral
• Intravenous
• Rectal
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Hepatic Encephalopathy Drugs Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
